Genetic interaction of P2X7 receptor and VEGFR-2 polymorphisms identifies a favorable prognostic profile in prostate cancer patients
Metrics: PDF 1639 views | HTML 1780 views | ?
Anna Solini1, Vittorio Simeon2, Lisa Derosa3, Paola Orlandi1, Chiara Rossi1, Andrea Fontana3, Luca Galli3, Teresa Di Desidero1, Anna Fioravanti1, Sara Lucchesi4, Luigi Coltelli4, Laura Ginocchi4, Giacomo Allegrini4, Romano Danesi1, Alfredo Falcone3, Guido Bocci1
1Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
2Laboratory of Pre-clinical and Translational Research, IRCCS - CROB Referral Cancer Center of Basilicata, Rionero in Vulture, Potenza, Italy
3Oncology Unit 2, University Hospital of Pisa, Pisa, Italy
4Division of Medical Oncology, Pontedera Hospital, Azienda USL of Pisa, Pontedera, Italy
Guido Bocci, e-mail: email@example.com
Keywords: survival dimensionality reduction analysis, P2X7 receptor, VEGFR-2, polymorphisms, prostate cancer
Received: April 07, 2015 Accepted: August 10, 2015 Published: August 21, 2015
VEGFR-2 and P2X7 receptor (P2X7R) have been described to stimulate the angiogenesis and inflammatory processes of prostate cancer. The present study has been performed to investigate the genetic interactions among VEGFR-2 and P2X7R SNPs and their correlation with overall survival (OS) in a population of metastatic prostate cancer patients. Analyses were performed on germline DNA obtained from blood samples and SNPs were investigated by real-time PCR technique. The survival dimensionality reduction (SDR) methodology was applied to investigate the genetic interaction between SNPs. One hundred patients were enrolled. The SDR software provided two genetic interaction profiles consisting of the combination between specific VEGFR-2 (rs2071559, rs11133360) and P2X7R (rs3751143, rs208294) genotypes. The median OS was 126 months (95% CI, 115.94–152.96) and 65.65 months (95% CI, 52.95–76.53) for the favorable and the unfavorable genetic profile, respectively (p < 0.0001). The genetic statistical interaction between VEGFR-2 (rs2071559, rs11133360) and P2X7R (rs3751143, rs208294) genotypes may identify a population of prostate cancer patients with a better prognosis.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.